Zoetis Q3: Strong Osteoarthritis Pain Franchise

I upgraded Zoetis (NYSE: ZTS ) to a 'Buy' rating in August 2024, highlighting the company's direct-to-customer strategy and investment in new products. Zoetis delivered a strong growth in Q3 FY24, with 14% year-over-year growth in both revenue and adjusted net income. Notably, their companion animalMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specia ...